Bronchodilator Drugs - Malta | Statista Market Forecast

The Bronchodilator Drugs market in Malta is expected to witness a significant increase in revenue, projected to reach US$4.54m by 2024.
This growth is anticipated to continue with an annual growth rate (CAGR 2024-2029) of 4.47%, leading to a market volume of US$5.65m by 2029.
When compared globally, it is noteworthy that United States is expected to generate the highest revenue in this market, reaching a staggering US$17.34bn in 2024.
Bronchodilator drug usage in Malta has seen a significant increase due to the country's high prevalence of respiratory diseases.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are widely used in Malta to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis.

Customer preferences: Maltese customers prefer inhalers over other forms of bronchodilator drugs such as tablets or syrups. This is due to the convenience and ease of use of inhalers, which allow for quick relief of symptoms. Additionally, customers tend to prefer branded drugs over generic ones, as they perceive them to be of higher quality.

Trends in the market: The Bronchodilator Drugs market in Malta has been steadily growing over the past few years. This can be attributed to the increasing prevalence of respiratory diseases in the country, as well as the growing awareness and diagnosis of these conditions. The market has also seen a shift towards more advanced and innovative inhaler technologies, such as dry powder inhalers and smart inhalers, which offer improved efficacy and ease of use.

Local special circumstances: Malta has a high prevalence of respiratory diseases, with asthma being one of the most common chronic conditions in the country. This is due to a combination of factors, including air pollution, smoking, and genetic predisposition. Additionally, Malta has a high elderly population, who are more susceptible to respiratory diseases and require more frequent use of bronchodilator drugs.

Underlying macroeconomic factors: The healthcare sector in Malta is highly regulated, with the government playing a significant role in the provision and funding of healthcare services. The country has a publicly-funded healthcare system, which provides free or heavily subsidized healthcare to all citizens and residents. This has led to a high demand for bronchodilator drugs, as they are widely prescribed and subsidized by the government. However, the government’s budget constraints and increasing healthcare costs may impact the availability and affordability of these drugs in the future.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.